AMPLATZER versus Figulla occluder for transcatheter patent foramen ovale closure

Daniela Trabattoni, Achille Gaspardone, Gregory A. Sgueglia, Franco Fabbiocchi, Gaetano Gioffrè, Piero Montorsi, Giuseppe Calligaris, Maria Iamele, Antonella De Santis, Antonio L. Bartorelli

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aims: The aim of this observational study was to compare acute and 12-month results of percutaneous closure of patent foramen ovale (PFO) with two occluder devices. Methods and results: Between June 2007 and October 2014, 406 consecutive patients (48.1±13.3 years, 243 women) underwent percutaneous PFO closure with either the AMPLATZER (n=179) or the Figulla (n=227) device after a stroke or a transient ischaemic attack ascribed to the PFO. A right-to-left shunt grade >1 was previously detected in all patients and atrial septal aneurysm was present in 111 (27.5%) patients. Patients were followed up with a contrast transthoracic echocardiogram and clinically at 24 hours, six months, and 12 months after the procedure. A high procedural success was observed in both groups. Despite a trend towards a higher incidence of acute residual shunt immediately after device deployment among Figulla occluder patients, a residual grade >2 right-to-left shunt was observed in 4.5% of patients, independently of the device used for PFO closure. The only difference reported after Figulla device implantation was a lower rate of supraventricular arrhythmias (9% vs. 17%, p=0.02). Conclusions: According to this two-centre study, PFO closure appears safe and effective with the Figulla occluder as well as with the AMPLATZER device.

Original languageEnglish
Pages (from-to)2092-2099
Number of pages8
JournalEuroIntervention
Volume12
Issue number17
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Patent Foramen Ovale
Equipment and Supplies
Transient Ischemic Attack
Observational Studies
Aneurysm
Cardiac Arrhythmias
Stroke
Incidence

Keywords

  • Closure devices
  • Patent foramen ovale
  • Percutaneous closure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

AMPLATZER versus Figulla occluder for transcatheter patent foramen ovale closure. / Trabattoni, Daniela; Gaspardone, Achille; Sgueglia, Gregory A.; Fabbiocchi, Franco; Gioffrè, Gaetano; Montorsi, Piero; Calligaris, Giuseppe; Iamele, Maria; De Santis, Antonella; Bartorelli, Antonio L.

In: EuroIntervention, Vol. 12, No. 17, 01.04.2017, p. 2092-2099.

Research output: Contribution to journalArticle

Trabattoni, Daniela ; Gaspardone, Achille ; Sgueglia, Gregory A. ; Fabbiocchi, Franco ; Gioffrè, Gaetano ; Montorsi, Piero ; Calligaris, Giuseppe ; Iamele, Maria ; De Santis, Antonella ; Bartorelli, Antonio L. / AMPLATZER versus Figulla occluder for transcatheter patent foramen ovale closure. In: EuroIntervention. 2017 ; Vol. 12, No. 17. pp. 2092-2099.
@article{18b538a09d8045509ba9f19d47b5f22d,
title = "AMPLATZER versus Figulla occluder for transcatheter patent foramen ovale closure",
abstract = "Aims: The aim of this observational study was to compare acute and 12-month results of percutaneous closure of patent foramen ovale (PFO) with two occluder devices. Methods and results: Between June 2007 and October 2014, 406 consecutive patients (48.1±13.3 years, 243 women) underwent percutaneous PFO closure with either the AMPLATZER (n=179) or the Figulla (n=227) device after a stroke or a transient ischaemic attack ascribed to the PFO. A right-to-left shunt grade >1 was previously detected in all patients and atrial septal aneurysm was present in 111 (27.5{\%}) patients. Patients were followed up with a contrast transthoracic echocardiogram and clinically at 24 hours, six months, and 12 months after the procedure. A high procedural success was observed in both groups. Despite a trend towards a higher incidence of acute residual shunt immediately after device deployment among Figulla occluder patients, a residual grade >2 right-to-left shunt was observed in 4.5{\%} of patients, independently of the device used for PFO closure. The only difference reported after Figulla device implantation was a lower rate of supraventricular arrhythmias (9{\%} vs. 17{\%}, p=0.02). Conclusions: According to this two-centre study, PFO closure appears safe and effective with the Figulla occluder as well as with the AMPLATZER device.",
keywords = "Closure devices, Patent foramen ovale, Percutaneous closure",
author = "Daniela Trabattoni and Achille Gaspardone and Sgueglia, {Gregory A.} and Franco Fabbiocchi and Gaetano Gioffr{\`e} and Piero Montorsi and Giuseppe Calligaris and Maria Iamele and {De Santis}, Antonella and Bartorelli, {Antonio L.}",
year = "2017",
month = "4",
day = "1",
doi = "10.4244/EIJ-D-15-00499",
language = "English",
volume = "12",
pages = "2092--2099",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "EuroPCR",
number = "17",

}

TY - JOUR

T1 - AMPLATZER versus Figulla occluder for transcatheter patent foramen ovale closure

AU - Trabattoni, Daniela

AU - Gaspardone, Achille

AU - Sgueglia, Gregory A.

AU - Fabbiocchi, Franco

AU - Gioffrè, Gaetano

AU - Montorsi, Piero

AU - Calligaris, Giuseppe

AU - Iamele, Maria

AU - De Santis, Antonella

AU - Bartorelli, Antonio L.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Aims: The aim of this observational study was to compare acute and 12-month results of percutaneous closure of patent foramen ovale (PFO) with two occluder devices. Methods and results: Between June 2007 and October 2014, 406 consecutive patients (48.1±13.3 years, 243 women) underwent percutaneous PFO closure with either the AMPLATZER (n=179) or the Figulla (n=227) device after a stroke or a transient ischaemic attack ascribed to the PFO. A right-to-left shunt grade >1 was previously detected in all patients and atrial septal aneurysm was present in 111 (27.5%) patients. Patients were followed up with a contrast transthoracic echocardiogram and clinically at 24 hours, six months, and 12 months after the procedure. A high procedural success was observed in both groups. Despite a trend towards a higher incidence of acute residual shunt immediately after device deployment among Figulla occluder patients, a residual grade >2 right-to-left shunt was observed in 4.5% of patients, independently of the device used for PFO closure. The only difference reported after Figulla device implantation was a lower rate of supraventricular arrhythmias (9% vs. 17%, p=0.02). Conclusions: According to this two-centre study, PFO closure appears safe and effective with the Figulla occluder as well as with the AMPLATZER device.

AB - Aims: The aim of this observational study was to compare acute and 12-month results of percutaneous closure of patent foramen ovale (PFO) with two occluder devices. Methods and results: Between June 2007 and October 2014, 406 consecutive patients (48.1±13.3 years, 243 women) underwent percutaneous PFO closure with either the AMPLATZER (n=179) or the Figulla (n=227) device after a stroke or a transient ischaemic attack ascribed to the PFO. A right-to-left shunt grade >1 was previously detected in all patients and atrial septal aneurysm was present in 111 (27.5%) patients. Patients were followed up with a contrast transthoracic echocardiogram and clinically at 24 hours, six months, and 12 months after the procedure. A high procedural success was observed in both groups. Despite a trend towards a higher incidence of acute residual shunt immediately after device deployment among Figulla occluder patients, a residual grade >2 right-to-left shunt was observed in 4.5% of patients, independently of the device used for PFO closure. The only difference reported after Figulla device implantation was a lower rate of supraventricular arrhythmias (9% vs. 17%, p=0.02). Conclusions: According to this two-centre study, PFO closure appears safe and effective with the Figulla occluder as well as with the AMPLATZER device.

KW - Closure devices

KW - Patent foramen ovale

KW - Percutaneous closure

UR - http://www.scopus.com/inward/record.url?scp=85021105823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021105823&partnerID=8YFLogxK

U2 - 10.4244/EIJ-D-15-00499

DO - 10.4244/EIJ-D-15-00499

M3 - Article

AN - SCOPUS:85021105823

VL - 12

SP - 2092

EP - 2099

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

IS - 17

ER -